Entyvio (vedolizumab) is used to treat ulcerative colitis (UC) and Crohn’s disease. In these conditions, the body’s immune system attacks healthy tissues in the gut, causing abdominal pain, blood in the stool, and diarrhea.
People with Crohn’s and ulcerative colitis (UC) have chronic inflammation of the gut with an excess of white blood cells that target the gastrointestinal (GI) tract. The alpha-4-beta-7 T-cell attaches to the MAdCAM-1 receptor in the gut, causing increased inflammation.
Entyvio belongs to a class of drugs known as monoclonal antibodies and works by blocking this connection so that excess white blood cells can’t enter the gut tissue. Entyvio is very specialized to specifically target GI proteins only. When T-cells can’t enter the gut, inflammation is reduced as well as the symptoms of Crohn’s and UC.
Click here for additional side effects
Given at week 0, 2, 6, and then every 8 weeks
Before your infusion, it is important to drink plenty of water and come to your appointment hydrated. Additionally, you must alert us as soon as possible to any changes in your insurance to ensure that we are still an in-network provider for your infusion therapy.